Press Releases

Samsung BIO Insight

Scaling Up Quality and Flexibility with Trusted Partnership

Scaling Up Quality and Flexibility with Trusted Partnership images1 


When it comes to the challenges and trends biomanufacturers face, from market disruptions to the innovations in diverse and complex molecules, Samsung Biologics recognizes the evolving need for flexibility and quality in drug manufacturing. The company has invested in capacity and resources to ultimately give clients supply access in order to bring their product to market quickly. In this article, explore how Samsung Biologics is committed to working closely with its customers, which range from large biopharma to growing biotech companies, to deliver flexible and quality solutions that will facilitate their journey seamlessly.   

 

 

Driving flexibility to manage demand


Scaling Up Quality and Flexibility with Trusted Partnership images2
 
 

Plant1
30,000L
5K x6
Plant2
154,000L
15K x10
1K x2
1K x2
Plant3
180,000L
15K x12
Plant4
240,000L
15K x12
10K x6
Plant5
180,000L
15K x12

Samsung Biologics is continuously expanding its manufacturing capacity while keeping flexibility at the forefront. The company's four advanced manufacturing plants, including the newly completed Plant 4, are designed to swiftly adapt to the evolving needs of its diverse client base. 

"We offer a range of bioreactor capacities from 1,000 to 15,000 liters, enabling us to provide small to large scale production. With state-of-the-art facilities and optimized timeline, we consistently produce high-quality biopharmaceuticals that meet our clients' expectations," said Soyeon Ahn, Senior Director, Plant 4 Upstream and Downstream Manufacturing.


Strong client relationships at Samsung Biologics are forged through continuous efforts to identify and address improvement points during production. Regular evaluation sessions for each project focus on enhancing equipment and processes to maximize efficiency.

"We collaborate with clients to fine-tune process like control logics of critical parameters. These improvements not only enhance yield, but also contribute to a smoother production process," Ahn added. 



Ensuring quality at every phase 


Scaling Up Quality and Flexibility with Trusted Partnership images3
 

Quality management is a non-negotiable in biopharmaceutical manufacturing, and Samsung Biologics excels in this regard. The company has established thorough quality control measures for the entire production process, from cell culture conditions to comprehensive process monitoring and investigations.

"We're not just scaling up production; we're scaling up quality. Our commitment to quality management is unwavering, and it's reflected in every aspect of our operations," Ahn highlighted. 


Samsung Biologics maintains pristine conditions at each of its manufacturing sites, regularly inspecting the equipment. "Considering that most production disruptions result from equipment issues, our well-maintained and new facilities significantly contribute to the high quality of our products," Ahn added.

Fostering an environment of continuous improvement, the MSAT, Quality, and Facility teams work tirelessly to minimize risk and maintain operational excellence.



Adopting new technologies to improve efficiency


Scaling Up Quality and Flexibility with Trusted Partnership images4 


Samsung Biologics is taking steps to leverage digitalization throughout the entire manufacturing process. This commitment to innovation extends across all facilities, resulting in continuous improvements in productivity and operational efficiency. 


Scaling Up Quality and Flexibility with Trusted Partnership images5


In Plant 4, several cutting-edge technologies were introduced to bolster efficiency and quality. A single-use alternating tangential flow (ATF) filtration system significantly reduces contamination risks when changing products, ensuring a high level of product purity and safety. The company has not only increased product yield but also cut processing times, by incorporating a continuous solids discharge centrifuge ball to separate mixture of solids. 


Scaling Up Quality and Flexibility with Trusted Partnership images6 


Samsung Biologics has also introduced AxiChrom™ technology to prevent microbial contamination (bioburden) and simplify the purification column packing process. 

The upcoming fifth plant, set to be completed in 2025, will further integrate automation and digital transformation throughout the entire production process to improve efficiency and consistency.


Scaling Up Quality and Flexibility with Trusted Partnership images7 


By focusing on flexibility and quality management in its biopharmaceutical manufacturing operations, Samsung Biologics remains dedicated to providing the highest standard of manufacturing excellence.



Related Contents

Science & Technology Plan your CDMO search on a foundation for long-term success

Samsung BIO Insight Building a Sustainable Future from the Ground Up

Samsung BIO Insight Propelling Quality Through Innovation & Accumulated Expertise

Samsung BIO Insight Forging a trusted partnership in end-to-end drug development

Scaling Up Quality and Flexibility with Trusted Partnership images1


When it comes to the challenges and trends biomanufacturers face, from market disruptions to the innovations in diverse and complex molecules, Samsung Biologics recognizes the evolving need for flexibility and quality in drug manufacturing. The company has invested in capacity and resources to ultimately give clients supply access in order to bring their product to market quickly. In this article, explore how Samsung Biologics is committed to working closely with its customers, which range from large biopharma to growing biotech companies, to deliver flexible and quality solutions that will facilitate their 1.5;">Driving flexibility to manage demand


Scaling Up Quality and Flexibility with Trusted Partnership images2 

Plant1
30,000L
5K x6
Plant2
154,000L
15K x10
1K x2
1K x2
Plant3
180,000L
15K x12
Plant4
240,000L
15K x12
10K x6
Plant5
180,000L
15K x12


Samsung Biologics is continuously expanding its manufacturing capacity while keeping flexibility at the forefront. The company's four advanced manufacturing plants, including the newly completed Plant 4, are designed to swiftly adapt to the evolving needs of its diverse client base. 

"We offer a range of bioreactor capacities from 1,000 to 15,000 liters, enabling us to provide small to large scale production. With state-of-the-art facilities and optimized timeline, we consistently produce high-quality biopharmaceuticals that meet our clients' expectations," said Soyeon Ahn, Senior Director, Plant 4 Upstream and Downstream Manufacturing.


Strong client relationships at Samsung Biologics are forged through continuous efforts to identify and address improvement points during production. Regular evaluation sessions for each pro 1.5;">Samsung BIO Insight Forging a trusted partnership in end-to-end drug development

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION